Home » Newsletters » BioWorld

BioWorld

Dec. 15, 1992

View Archived Issues

IXSYS OFFERS TAILOR-MADE ANTIBODIES

ANTI-COMPLEMENT DRUG GOES ON TRIAL

TLC GETS HIGH PHASE II MARKS

ONCOGENE SIGNS $17M AGREEMENT

GILEAD FILES FOR SECONDARY

ENZON DRUG TO GET ORPHAN STATUS

CALGENE FILES FOR OFFERING

Today's news in brief
BioWorld
BioWorld briefs for Jan. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 17, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.